Losartan, Pembrolizumab, and Radiation for Head and Neck Cancer
This study is testing the safety and side effects of combining three treatments for head and neck squamous cell carcinoma that has returned, not responded to previous treatment, or spread to a few other places in the body. The treatments are losartan (a blood pressure medication that may help other cancer treatments), pembrolizumab (an immunotherapy that helps your body's immune system fight cancer), and stereotactic body radiation therapy (SBRT), a focused type of radiation. Researchers want to see if this combination is safe and how well it works to shrink tumors. You may be eligible if you have this type of head and neck cancer and are willing to undergo tumor biopsies. The study aims to enroll 24 participants, but its current status is unclear.
- Study design
- This is an interventional study designed to test the safety and effectiveness of a new treatment combination. It plans to enroll 24 participants.
- What's involved
- You would take losartan by mouth daily, receive SBRT 2-3 times a week for about 2 weeks, and then receive pembrolizumab intravenously every 3 weeks for up to one year. You will also have PET scans, tumor biopsies, and blood tests.
- Compensation
- Not stated in the trial record.
- Follow-up
- After treatment, you will be followed up at 30 days and then every 3 months for up to one year to monitor for side effects and disease progression.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT06211335
Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma
Recruiting
PHASE1Ages 18+InterventionalTreatmentUniversity of California, DavisInvestigator-initiated
~24 participants
Updated 2026-03-12 on ClinicalTrials.gov
What's tested:LosartanPembrolizumabStereotactic Body Radiation Therapy
At a glance
Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of treatment related adverse events
Measured over Up to 2 years
Conditions
Where it's being run
2 sites across 2 statesCalifornia1
Colorado1
Study leadership
- Shyam S.D. Rao, MD, PhD · PRINCIPAL_INVESTIGATOR · University of California, Davis
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Histologically or cytologically confirmed locoregionally recurrent, refractory, or oligometastatic (at most 4 lesions) squamous cell carcinoma of the head and neck not amenable to curative resection
p16 status known for base of tongue, soft palate, and tonsil cancers
Tumor amenable to sequential biopsies, and patients willing to undergo sequential tumor biopsies so long as the treating investigator considers them to be clinically safe
Prior radiotherapy to the head and neck is allowed. Disease should be limited to up to 4 sites of active disease in the head and neck and/or distant metastatic sites if deemed safely treatable by physician, or adjacent sites treatable in single contiguous target volume with a recommended maximum total tumor dimension (GTV) of \< 7.5 cm. However, larger volumes may be allowed after discussion with primary investigator (PI) and careful review of radiation dose constraints
Prior systemic therapy is allowed. Patients with locoregional relapses where radiation alone would be indicated are allowed to enroll without prior systemic therapy
Presence of measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) with a target on a computed tomography (CT) scan or magnetic resonance imaging (MRI) available for review
Combined positive score (CPS) \> 1%
Age ≥ 18 years at time of consent
Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1
Leukocytes ≥ 3 × 10\^9/L
Absolute neutrophil count ≥ 1.5 × 10\^9/L
Platelets ≥ 100 × 10\^9/L
Hemoglobin (Hgb) ≥ 9 g/dL, transfusions may be used to raise Hgb to ≥ 9 g/dL (no washout required)
Total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN)
Aspartate transaminase (AST) / alanine transaminase (ALT) ≤ 2.5 × institutional ULN
Creatinine within normal institutional limits OR creatinine clearance ≥ 30 mL/min/1.73 m\^2 for patients with creatinine above institutional ULN
The effects of losartan on the developing human fetus are unknown. For this reason, individuals of childbearing potential and male participants with partners of childbearing potential, must agree to use methods of contraception for the duration of study participation (including dosing interruptions) and for up to 3 months after last study treatment; or be surgically sterilized
Ability to understand and willingness to sign and date the informed consent form
Stated ability and willingness to adhere to the study visit schedule and protocol requirements
Exclusion
Nasopharyngeal carcinoma, salivary gland carcinoma or primary skin squamous cell carcinoma (SCC)
Prior treatment with an anti-PD-1, anti-PD-L1, or anti-PD-L2 antibody
Chemotherapy or other anti-cancer therapy within 3 weeks prior to study day 1
Hypersensitivity to losartan or any component of the formulation
Radiation therapy within 6 months prior to study day 1
Patients with disease surrounding \> 50% of the carotid
Participant who has not recovered to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade ≤ 1 from an adverse event (AE) due to previous cancer therapeutics (i.e., chemotherapy, radiation therapy, biologic therapy, and/or experimental therapy) with the exception of alopecia
Major surgery as assessed by the investigator (with the exception of diagnostic biopsy) within ≤ 28 days prior to study day 1 (patients must have completely recovered from any previous surgery prior to study day 1)
Clinically significant bleeding ≤ 4 weeks prior to study day 1
Requirement for parenteral antibiotics, or any active infection requiring parenteral antibiotic therapy within 4 weeks prior to study day 1
Clinically significant or uncontrolled diabetes mellitus (hemoglobin A1C ≤ 8.5%). Patients with diabetes mellitus treated with aliskiren ≤ 7 days prior to study day 1 are excluded
Active autoimmune disorders that have required systemic treatment with disease modifying agents, corticosteroids, or immunosuppressive drugs in the past 2 years are excluded. Patients with autoimmune disorder or well-managed or inactive autoimmune disorders, such as Hashimoto's thyroiditis, may be allowed at the discretion of the PI
Current use of systemic corticosteroids equivalent to \>10 mg of prednisone per day
Current use of angiotensin receptor blockers (ARBs) or angiotensin converting enzyme (ACE) inhibitors for management of hypertension
Clinically significant cardiovascular, pulmonary, endocrine, neurologic, gastrointestinal or genitourinary disease unrelated to underlying solid tumor that in the judgment of the investigator should preclude treatment with losartan
Any other active malignancy except for low-risk prostate cancer previously treated or under active surveillance, uncomplicated and cured basal cell carcinoma, or squamous cell carcinoma of the skin within 5 years of study entry
Known history of positive hepatitis C (HCV) antibody, hepatitis B (HBV) surface antigen (HbsAg and HBV core Ab positive), or human immunodeficiency virus (HIV) antibody results. Patients with positive antibody tests are eligible with negative viral loads
Administration of live, attenuated vaccine ≤ 28 days prior to study day 1. Administration of inactivated flu vaccines is allowed
Any prior treatment with losartan or other specific TGF-β-directed therapy
Treatment with another investigational drug or device, or approved therapy for investigational use ≤ 28 days prior to study day 1, or if the half-life of the previous product is known, within 5 times the half-life prior to study day 1, whichever may be longer
Pregnant or breast feeding
Any condition that in the opinion of the investigator would interfere with the participant's safety, compliance while on trial, or understanding or rendering of informed consent
What this trial measures
- Incidence of treatment related adverse eventsUp to 2 years
Classified by severity and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 and summarized using descriptive statistics in participants treated with dosage of the agent selected in the safety run.